Relationship of Mcl-1 isoforms, ratio p21WAF1/cyclin a, and Jun kinase phosphorylation to apoptosis in human breast carcinomas

Biochemical and Biophysical Research Communications

Volumn 297, Issue 4, 2002, Pages 943-949

  Rieber, Manuel ^a   Medina, Jose D ^a   Strasberg Rieber, Mary ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Acetyl furanonaphthoquinone; Cyclin dependent kinase inhibitors; Drug resistance; Phosphatase inhibitors; Proteasome

Indexed keywords

ACETYL FURANONAPHTHOQUINONE; CYCLIN A; ENZYME INHIBITOR; ISOPROTEIN; MUTANT PROTEIN; OKADAIC ACID; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEASOME INHIBITOR; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; QUINONE DERIVATIVE; UNCLASSIFIED DRUG; VANADIC ACID;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

APOPTOSIS; BREAST NEOPLASMS; CELL NUCLEUS; CHROMATIN; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; GENES, P53; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUPEPTINS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; OKADAIC ACID; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0036031827     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02312-4     Document Type: Article

References (27)

1. K.M. Kozopas, T. Yang, H.L. Buchan, P. Zhou, R.W. Craig, MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2, Proc. Natl. Acad. Sci. USA 90 (1993) 3516-3520.
2. M.L. Kuo, S.E. Chuang, M.T. Lin, S.Y. Yang, The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6, Oncogene 20 (2001) 677-685.
3. J.A. Vrana, C.K. Bieszczad, E.S. Cleaveland, Y. Ma, J.P. Park, T.K. Mohandas, R.W. Craig, An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum Deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-{rbeta}-D-Arabinofuranosylcytosine, Cancer Res. 62 (2002) 892-900.
4. C.M. Leu, C. Chang, C. Hu, Epidermal growth factor suppresses staurosporine-induced apoptosis by inducing mcl-1 via the MAP kinase pathway, Oncogene 19 (2000) 1665-1673.
5. W. Nieves-Neira, Y. Pommier, Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen, multifactorial relationships with topoisomerase I, protein kinase C, bcl-2, p53,MDM2 and caspase pathways, Int. J. Cancer 82 (1999) 396-404.
6. T. Yang, K.M. Kozopas, R.W. Craig, The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to those of Bcl-2, J. Cell Biol. 128 (1995) 1173-1184.
7. A.M. Domina, J.H. Smith, R.W. Craig, Myeloid cell leukaemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition, J. Biol. Chem. 275 (2000) 21688-21694.
8. J.M. Daly, C.B. Jannot, R.R. Beerli, D. Graus-Porta, F.G. Maurer, N.E. Hynes, Neu differentiation factor induces ErbB2 down-regulation and apoptosis in ErbB2-overexpressing breast tumor cells, Cancer Res. 58 (1998) 804-3811.
9. B. Jallal, J. Schlessinger, A. Ullrich, Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells, J. Biol. Chem. 267 (1992) 4357-4363.
10. W.G. An, R.C. Schnur, L. Neckers, M.V. Blagosklonny, Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity, Cancer Chemother. Pharmacol. 40 (1997) 60-64.
11. M. Strasberg Rieber, M. Rieber, Accesibility to DNA in carcinoma chromatin is promoted by nanomolar okadaic acid, effect on A-T rich DNA binding proteins, Cancer Res. 52 (1992) 6397-6399.
12. M.S. Sheikh, M. Garcia, Q. Zhan, Y. Liu, A.J. Fornace Jr., Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of bax protein in human breast carcinoma cells, Cell Growth Differ. 7 (1996) 1599-1607.
13. D.D. Bannerman, J.C. Tupper, W.A. Ricketts, C.F. Bennett, R.K. Winn, J.M. Harlan, A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis, J. Biol. Chem. 276 (2001) 14924-14932.
14. M. Rieber, M. Strasberg Rieber, Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21WAF1 in human melanoma cells, Int. J. Cancer 86 (2000) 462-467.
15. K. Hirai, J. Koyama, J. Pan, E. Simamura, H. Shimada, T. Yamori, S. Sato, T. Tagahara, T. Tsuruo, Furanonaphthoquinone analogs possesing antitumor activity compared to normal cells, Cancer Detect. Prev. 23 (1999) 539-550.
16. C.M. Simbulan-Rosenthal, D.S. Rosenthal, S. Iyer, H. Boulares, M.E. Smulson, Involvement of PARP and poly (ADP-ribosyl)ation in the early stages of apoptosis and DNA replication, Mol. Cell Biochem. 193 (1999) 137-148.
17. M. Strasberg Rieber, D.R. Welch, M.E. Miele, M. Rieber, p53-independent increase in p21WAF1 and reciprocal down-regulation of cyclin A and proliferating cell nuclear antigen in growth arrest of human melanoma cells, Cell Growth Differ. 7 (1996) 197-202.
18. C. Naujokat, O. Sezer, H. Zinke, A. Leclere, S. Hauptmann, K. Possinger, Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells, Eur. J. Haematol. 65 (2000) 221-236.
19. D. Resnitzky, L. Hengst, S.I. Reed, Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1, Mol. Cell Biol. 15 (1995) 4347-4352.
20. C.R. Weston, R.J. Davis, The JNK signal transduction pathway, Curr. Opin. Genet. Dev. 12 (2002) 14-21.
21. J.C. Hardwick, G.R. van den Brink, G.J. Offerhaus, S.J. van Deventer, M.P. Peppelenbosch, NF-κB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps, Oncogene 20 (2001) 819-827.
22. C. Palacios, M.K. Collins, G.R. Perkins, The JNK phosphatase M3/6 is inhibited by protein-damaging stress, Curr. Biol. 11 (2001) 1439-1443.
23. J.L. Todd, J.D. Rigas, L.A. Rafty, J.M. Denu, Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK), Oncogene 21 (2002) 2573-2583.
24. C.J. Dougherty, L.A. Kubasiak, H. Prentice, P. Andreka, N.H. Bishopric, K.A. Webster, Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress, Biochem. J. 362 (2002) 561-571.
25. S. Derenne, B. Monia, N.M. Dean, J.K. Taylor, M.J. Rapp, J.L. Harousseau, R. Bataille, M. Amiot, Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells, Blood 100 (2002) 194-199.
26. B.L. Bennett, D.T. Sasaki, B.W. Murray, E.C. O'Leary, S.T. Sakata, W. Xu, J.C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S.S. Bhagwat, A.M. Manning, D.W. Anderson, SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase, Proc. Natl. Acad. Sci. USA 98 (2001) 13681-13686.
27. M. Shin, C. Yan, D. Boyd, An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression, Biochim. Biophys. Acta 1589 (2002) 311-316.